Qlife Holding

Qlife Holding AB: The Letter of Intent with Hipro Biotechnology Co., Ltd. regarding reverse takeover has been extended

Källa: MFN
Neutral

Sammanfattning

Qlife Holding AB har förlängt avsiktsförklaringen gällande ett potentiellt omvänt förvärv med Hipro Biotechnology Co., Ltd. Avtalet förlängs till 31 december 2025, med oförändrade villkor. Parterna är fortsatt engagerade i transaktionen.

Analys

Förlängningen av avsiktsförklaringen indikerar att förhandlingarna om det omvända förvärvet med Hipro Biotechnology fortsätter. Detta är en procedurmässig uppdatering som inte ger någon ny finansiell information. Aktieägarna behöver avvakta ett definitivt avtal för att kunna bedöma transaktionens materiella effekter. Den strategiska rationalen bakom transaktionen kvarstår enligt bolaget.

Insikter

  • • Förlängningen av avsiktsförklaringen skjuter fram ett potentiellt beslut om ett omvänt förvärv.
  • • Ingen ny finansiell information eller konkreta detaljer om transaktionen presenteras i detta skede.
  • • Aktieägarna måste invänta ett undertecknat aktieöverlåtelseavtal för att kunna bedöma transaktionens materiella effekter.

Qlife Holding AB ("Qlife" or the "Company") announces an extension of the Letter

of Intent regarding a potential reverse takeover (the "Transaction") with Hipro

Biotechnology Co., Ltd. ("Hipro"). The Transaction was announced by the Company

through a press release on 5 June 2025. The term and exclusivity of the Letter

of Intent have been extended, and the Transaction would be conditional upon,

inter alia, the signing of a share purchase agreement no later than 31 December

2025. The other material terms and conditions of the Transaction as previously

communicated by the Company remain unchanged.

Qlife Holding AB ("Qlife" or the "Company") announces an extension of the Letter of Intent regarding a potential reverse takeover (the "Transaction") with Hipro Biotechnology Co., Ltd. ("Hipro"). The Transaction was announced by the Company through a press release on 5 June 2025. The term and exclusivity of the Letter of Intent have been extended, and the Transaction would be conditional upon, inter alia, the signing of a share purchase agreement no later than 31 December 2025. The other material terms and conditions of the Transaction as previously communicated by the Company remain unchanged.

The parties remain fully committed to the strategic rationale of the transaction and are aligned in their intent to execute it as outlined in the Letter of Intent.

For more information about the intended terms of the Transaction, please refer to the press release that was published on 5 June 2025 "Qlife Holding AB: Qlife enters letter of intent with Hipro Biotechnology Co., Ltd. to join forces through a reverse takeover".

For more information, please contact:

Thomas Warthoe, CEO

tw@egoo.health

+45 21 63 35 34

About Qlife

Qlife is a Swedish company based in Göteborg, which develops and markets an innovative medical technology platform, Egoo.Health ("Egoo"), with the goal of giving people access to clinical biomarker data when testing at home. The company is listed on the Nasdaq First North Growth Market (ticker: QLIFE). G&W Fondkommission is the Company's Certified Adviser. For additional information, please visit www.qlifeholding.com.

Fler nyheter från Qlife Holding

Relaterade pressmeddelanden och bolagshändelser från samma bolag.

Se bolagssidan